US 12,331,061 B2
Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof
Jie Fan, Brooklyn, NY (US); Wei He, Brooklyn, NY (US); and Ke Liu, Brooklyn, IN (US)
Assigned to Accutar Biotechnology Inc., Brooklyn, NY (US)
Appl. No. 17/604,014
Filed by ACCUTAR BIOTECHNOLOGY INC., Brooklyn, NY (US)
PCT Filed Apr. 17, 2020, PCT No. PCT/US2020/028767
§ 371(c)(1), (2) Date Oct. 15, 2021,
PCT Pub. No. WO2020/214952, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/835,825, filed on Apr. 18, 2019.
Prior Publication US 2022/0220124 A1, Jul. 14, 2022
Int. Cl. C07D 495/14 (2006.01); C07D 211/88 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01)
CPC C07D 495/14 (2013.01) [C07D 211/88 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01)] 36 Claims
 
1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
X1, X2, X3, X4, and X5 are independently selected from C-Q, CH, and N;
R1, R1′ and R2 are independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, halo, hydroxy, and sulfhydryl, each of which is substituted with 0, 1, 2, or 3 R4, wherein R1 and R1′ can be connected to form a 3 to 6 member heterocyclic or heteroaryl ring, and R1 and R2 can be connected to form a 5 to 7 member heterocyclic or heteroaryl ring;
Q is

OG Complex Work Unit Chemistry
p is 1;
L is a linker of 1 to 22 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR3, S, SO, SO2, C2-alkenyl, C2-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which can be substituted with 0, 1, 2, or 3 R4;
T is a targeting ligand;
R3 is independently selected from H, C1-C6 alkyl, aryl, heteroaryl, and acyl, where acyl can contain C1-C6 alkyl, C1-C6 cycloalkyl, aryl and heteroaryl, each of which can be substituted with 0, 1, 2, or 3 R4; and
each R4 is independently selected from C1-C6 alkyl, halo, cyano, and hydroxyl.